Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.73 |
| ▸ | IGF1R | P08069 | 7/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | INSR | P06213 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974228 | 0.89 | EGFR (0.73) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17385150 | 0.89 | EGFR (0.73) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL22994899 | 0.88 | EGFR (0.63) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17384841 | 0.87 | EGFR (0.71) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17384836 | 0.87 | EGFR (0.74) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17384834 | 0.87 | EGFR (0.75) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17831506 | 0.86 | EGFR (0.58) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL17385151 | 0.85 | EGFR (0.66) | EGFRIGF1RKCNH2INSRCDK2 | |
| SCHEMBL17373076 | 0.85 | EGFR (1.00) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL17553624 | 0.84 | EGFR (0.62) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| CN-106458969-A | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016029839-A1 | (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE | 四川海思科制药有限公司 | 2016-03-03 | — | — | WO | disclosed |
| WO-2015195228-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885IGF1R 404/4885KCNH2 4416/4885 |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885IGF1R 404/4885KCNH2 4416/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | EGFR 2/4885IGF1R 404/4885KCNH2 4416/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885IGF1R 404/4885KCNH2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.